The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How has acute myeloid leukemia treatment for elderly people changed in 2021?
Tapan Kadia
September 21, 2021
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, Know AML spoke to Tapan M. Kadia, MD Anderson Cancer Center, Houston, US. We asked, How has acute myeloid leukemia treatment in elderly people changed in 2021? Kadia outlines how lower intensity therapies, such as hypomethylating agents, compare to traditional chemotherapy in terms of toxicity and efficacy, as well as the VIALE-A trial, where venetoclax was shown to have significantly improved response rates and overall survival. Finally, Kadia explains the future of acute myeloid leukemia treatment, including stem cell transplants and genetic analysis, allowing treatment regimes to be best tailored to patients.
To what extent do you agree with the following statements?
Please rate between 1 and 5, with 1 being 'strongly disagree' and 5 being 'strongly agree'.
